The U.S. Capitol building in Washington, D.C. Photo: Christine Schiffner/ALM It's Time to Take Action on PBMs' Anti-Competitive Practices, Lawmakers Say
Industry says any statutory or regulatory push must examine the full prescription drug supply chain.
May 24, 2023 at 06:54 PM
4 minute read
Pharmaceuticals
Congress may give U.S. regulators greater oversight of pharmacy benefit managers amid Federal Trade Commission concern that these entities might be using anti-competitive business practices to inflate drug prices.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'Fire All the Bullets Now': EEOC Enforcements Surge
- 4'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
- 5Suspect in Courthouse Bombing Was Targeting Judge, Deputies, Say Prosecutors
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
